Back to Journal

SM Ophthalmology Journal

Expulsive Suprachoroidal Hemorrhage during Subluxated Lens Surgery: A Case Report

[ ISSN : 3068-0743 ]

Abstract Citation CASE PRESENTATION DISCUSSION REFERENCES
Details

Received: 18-Jul-2024

Accepted: 07-Aug-2024

Published: 09-Aug-2024

Kuo Zhao¹, Jun Ni¹, Xuegang Su¹, Qiang Li¹ and Fei Leng²*

¹Department of Ophthalmology, Shunyi Maternal and Children’s Hospital of Beijing Children’s Hospital, Beijing 101300, China
²Department of Ophthalmology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China

Corresponding Author:

Fei Leng, Department of Ophthalmology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China.

Abstract

Patient was a 59-year-old man who presented with progressive visual blurring in his right eye for 2 weeks and was admitted on November 6, 2023. The patient reported that he experienced progressive visual blurring after using a trigger point gun to massage the right eye socket 2 weeks prior, which worsened upon lying down.

Citation

Zhao K, Ni J, Su X, Li Q, Leng F (2024) Preclinical Characteriza tion of GST-HG141, a Novel Hepatitis B Virus Capsid Assembly Modulator. SM Opthalmol J. 2024; 5(1): 1016.

CASE PRESENTATION

Patient was a 59-year-old man who presented with progressive visual blurring in his right eye for 2 weeks and was admitted on November 6, 2023. The patient reported that he experienced progressive visual blurring after using a trigger point gun to massage the right eye socket 2 weeks prior, which worsened upon lying down. There was no eye strain or eye pain. The patient had a history of hypertension for 10 years, which was controlled with oral medication, with stable blood pressure, ranging from 140/85 mmHg. The patient’s unaided visual acuity in the right eye was 0.3, while his Corrected Distance Visual Acuity (CDVA) with + 0.50/+ 2.00 × 87 = 0.3 and an Intraocular Pressure (IOP) of 15 mmHg was noted. The anterior chamber depth was deepened, and the iris, lens, and zonules were found to be trembling. There was also a cloudy lens, and upon dilating the pupil, a lower portion of the lens was visible (Figure 1).

Figure 1: Patient’s prone position during surgery.

The unaided visual acuity in the left eye was 0.8, while the CDVA with +0.50/+0.75×177=1.0 and an IOP of 16mmHg was noted. The anterior chamber depth was normal, and there was no trembling of the iris, lens, or zonules. The lens was clear. The diagnosis upon admission was right lens subluxation; right traumatic cataract; and hypertension. The planned procedure was anterior segment vitrectomy plus cataract extraction with intraocular lens suspension.

After admission, the patient was treated with lidocaine injection intraocularly under orbital anesthesia, and a scleral tunnel incision was made above the nose and temporal area, remove the anterior vitreous, and intact extract the lens capsule (Figure 2).

Figure 2: Remove the anterior vitreous, and intact extract the lens capsule

The main incision was sutured partially, the anterior segment of the vitreous body was removed, and the patient experienced eye pain and restlessness. A grayish-black elevation was subsequently found on the temporal side of the fundus, and the range of the elevation gradually increased. A large amount of viscoelastic agent was quickly injected, the surgical incision was sutured, and hemorrhage in the vitreous cavity was seen (Figure 3).

Figure 3: A grayish-black elevation was subsequently found on the temporal side of the fundus. A large amount of viscoelastic agent was quickly injected, the surgical incision was sutured, and hemorrhage in the vitreous cavity was seen.

The surgery was terminated. Postoperative patient had high IOP, which was controlled at 20-30 mmHg by 20% mannitol injection, betaxolol eye drops, brinzolamide eye drops, anterior chamber drainage, and atropine sulfate and corticosteroids for anti-inflammation.

On the first day after surgery, B-ultrasound showed a choroidal detachment, with a high to moderate echogenicity in the choroidal space (Figure 4).

Figure 4: On the first day after surgery, you can see a choroidal detachment, and the suprachoroidal space shows a moderate to high echogenicity

Ten days later, the IOP stabilized, the right eye visual acuity was 0.01, CDVA was 0.6, and the B-ultrasound showed that the echo in the supraciliary space was improved compared with the first day after surgery, and there is a temporal side choroidal detachment visible in the fundus (Figure 5).

Figure 5: On the 10th day after surgery, high-to-moderate echogenicity was seen in the suprachoroidal space, and a temporal choroidal detachment was visible on the fundus.

The patient was followed up regularly, and on postoperative week 3, the degree of choroidal detachment can be clearly improved by ultrasound examination (Figure 6).

Figure 6: The detachment of the choroid was significantly improved by the third week after surgery.

One month after surgery, a B ultrasound scan shows that the choroid has fully retracted, and the right eye visual acuity was 0.02, CDVA +10.75/-1.00×51=0.7, IOP 14mmHg. Two months post-operatively, the patient’s unaided visual acuity was 0.02, while the CDVA with + 10.50/-0.50*47=1.0. The IOP was 14mmHg, and B-ultrasound showed the choroidal reattachment (Figure 7)

The patient was scheduled to undergo anterior segment vitrectomy and intraocular lens suspension surgery on January 8, 2024, and the surgery was successful. The patient’s uncorrected visual acuity was 0.8 in the first week postoperatively, CDVA was +0.25/-0.25×98=0.9, the retina and choroid were in place (Figure 8),

Figure 8: After the suspension surgery, a B-ultrasound examination in the first week shows that the retina and choroid are in place

and the patient was followed up regularly postoperatively. The patient’s uncorrected visual acuity was 1.0 at 2 months postoperatively, and the CDVA was +0.50/-0.50×170=1.0, the lens position was normal (Figure 9),

Figure 9: A photograph taken by a slit lamp 2 months after surgery

and the retina and choroid were in place (Figure 10).

Figure 10: B-ultrasound and fundus photography at 2 months post-operation.

DISCUSSION

Explosive Suprachoroidal Hemorrhage (ESCH) is a rapid, poorly prognostic complication of intraocular surgery with a low incidence. Risk factors include: advanced age, hypertension, oral anticoagulants, glaucoma, high myopia, history of intraocular surgery, in addition to coughing, holding breath, Valsalva maneuver, high intraocular pressure before surgery and sudden decrease in intraocular pressure during surgery, loss of vitreous, posterior eye block, high intraoperative blood pressure, and prolonged surgical time, etc. The current pathogenesis is not clear, and it is generally believed that it is caused by a sudden drop in intraocular pressure, resulting in choroidal and ciliary effusion, leading to tear of the ciliary artery posterior [1]. Once explosive suprachoroidal hemorrhage occurs, the patient will experience sudden and severe eye pain, restlessness, and the surgeon should be vigilant and immediately stop the operation and close the incision. With the displacement of intraocular tissue, the intraocular tissue should be repositioned as soon as possible. Lakhanpal observed the rabbit eye model and found that immediate scleral incision drainage after hemorrhage would cause increased bleeding and blood entering the vitreous cavity and retina. This confirmed that immediate scleral incision drainage during surgery was more harmful than beneficial [2].

Some studies suggest that small, localized, and limited hemorrhages located between the ciliary margin and the equator, as well as cases where retinal adhesion resolves within 2 weeks, may have the potential for spontaneous absorption through conservative treatment and can preserve some visual function [3,4]. Other studies suggest that hemorrhages involving the macula, hemorrhages not involving the macula but exceeding two quadrants, retinal detachment, retinal adhesion, vitreous hemorrhage, vitreous entrapment, persistent high intraocular pressure, residual crystalline lens after cataract surgery, uncontrollable ocular pain, etc. require surgical treatment [5]. The surgical indication is generally 7-14 days, considering that the inflammatory response has been controlled, the blood clot has liquefied, and drainage is facilitated, thereby reducing the risk of recurrent bleeding and damage to the retina. The surgical methods include: scleral incision drainage combined with anterior chamber shaping, vitrectomy combined with silicone oil filling, and the application of recombinant tissue Plasminogen Activator (r-tPA) among others. The suspected precipitating factors in this case were hypertension and a history of trauma. The patient’s postoperative prognosis was good, which may have been related to the timely detection and diagnosis, timely filling of viscoelastic agents and closure of the incision to maintain intraocular pressure, which controlled the bleeding, limited its extent, prevented the displacement of intraocular contents, and allowed for conservative treatment of hemorrhage absorption after surgery.

Currently, the treatment options for ESCH are diverse and the effectiveness varies. The main approach is to prevent it. First, pay attention to the risk factors of ESCH and take measures such as controlling blood pressure and intraocular pressure before surgery. Second, maintain stable intraocular pressure during surgery and try to shorten the surgery time and keep the patient relaxed. Finally, instruct the patient to avoid strenuous exercise and pressure on the eye after surgery. If bleeding occurs, diagnose and close the incision in time, maintain intraocular pressure, and improve the patient’s postoperative visual effect.

REFERENCES

1. Savastano A, Rizzo S, Savastano MC, Piccirillo V, Forte R, Sbordone S, et al. Choroidal effusion and suprachoroidal hemorrhage during phacoemulsification: intraoperative management to prevent expulsive hemorrhage. Eur J Ophthalmol. 2016; 26(4): 338-341. doi: 10.5301/ejo.5000707. Epub 2015 Nov 6. PMID: 26559935.

2. Lakhanpal V. Experimental and clinical observations on massive suprachoroidal hemorrhage. Trans Am Ophthalmol Soc. 1993; 91: 545-652. PMID: 8140705; PMCID: PMC1298482.

3. Lee SJ, Lee JH, Park SW, Kim M, Han SB. Spontaneous resolution of massive expulsive suprachoroidal hemorrhage with good long term visual outcome: a case report. Int Med Case Rep J. 2015; 8: 185-187. doi: 10.2147/IMCRJ.S92007. PMID: 26392789; PMCID: PMC4573076

4. Wang LC, Yang CM, Yang CH, Huang JS, Ho TC, Lin CP, et al. Clinical characteristics and visual outcome of non-traumatic suprachoroidal haemorrhage in Taiwan. Acta Ophthalmol. 2008; 86(8): 908-912. doi: 10.1111/j.1755-3768.2008.01266.x. Epub 2008 Jul 8. PMID: 18631331

5. Meier P, Wiedemann P. Massive suprachoroidal hemorrhage: secondary treatment and outcome. Graefes Arch Clin Exp Ophthalmol. 2000; 238(1): 28-32. doi: 10.1007/s004170050005. PMID: 10664049

Other Articles

Article Image 1

Application of Anti-Scarring Drugs and Drug Delivery Systems in Glaucoma Surgeries

Anti-scarring Drugs And Drug Delivery systems (DDSs) that are more effective and safer than mitomycin C have been sought to improve the outcome of glaucoma filtration surgeries. Drugs that selectively inhibit wound healing, including anti-transforming growth factor-β and anti-vascular endothelial growth factor antibodies, have been investigated, although their advantages are yet to be verified in humans. In addition, novel sustained release DDSs with fewer toxic effects have been studied for application after glaucoma surgeries. Several potential biomaterials for such DDSs, including gelatin hydrogel, have been introduced.

Tetsuya Sugiyama


Article Image 1

Biorbital Lymphoma with Severe Exophthalmos

A 34-year-old man presented with binocular proptosis for half a year and sight lost for seven days. The patient had a facial lymphoma resection and postoperative chemotherapy five years ago.

Dajiang Wang¹ and Boyan Fang²*


Article Image 1

Research Progress and Human Clinical Trials of Mesenchymal Stem Cells in Ophthalmology: A Mini Review

Ocular diseases are devastating as most of them would cause irreversible visual impairment and blindness. Conceptually, cell replacement therapy with new ocular cells generated by ocular stem cells can substitute the degenerated or damaged cells in the diseased tissue. This concept has first been applied in the limbal transplantation by limbal progenitor cells. Unfortunately, patients with limbal stem cell deficiency and the endogenous progenitor cells present in human corneal endothelium as well as retina have limited regenerative power. In recent decades, other stem cell sources for ocular cell regeneration have been explored and are now feasible with the use of pluripotent stem cells, such as the embryonic stem cells (ESCs) and the induced pluripotent stem cells (iPSCs). Nevertheless, autologous transplantation would not be applicable using ESCs, whereas the variability of reprogramming methods as well as genetic instability of iPSCs has hindered their direct applications. Alternatively, human adult stem cells, such as hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) are found throughout the body and can be efficiently isolated from patients while maintaining the characteristics of self-renewal and multipotency. Superiorly, adult stem cells harness the potential to protect the ocular cells, where MSCs are able to modulate the microenvironments of the diseased eye for neuroprotection. This article compiled the current progress of MSCs in ocular research. Moreover, the updated clinical trials of adult stem cells in ocular diseases are summarized. In addition, potential challenges and future prospects of stem cell research in ophthalmology would also be discussed.

Tsz Kin Ng* and Jasmine Sum-Yee Yung


Article Image 1

Bilateral Extramacular Choroidal Neovascularization in Wet Age-Related Macular Degeneration

Purpose: Choroidal neovascularization is a common complication following several retinal conditions, most commonly age-related macular degeneration (AMD). We present a case of bilateral extramacular choroidal neovascularization in a patient with wet AMD.

Methods/Patients: Interventional Case Report. Clinical, radiologic, and angiographic correlation.

Results: An 89 year old Caucasian male with Age-related Macular Degeneration (AMD) developed bilateral vitreous hemorrhages and subretinal hemorrhages after which were noted bilateral extramacular choroidal neovascular membranes. The vitreous hemorrhage in the left eye cleared on its own, while vitrectomy was performed in the right eye. Bevacizumab (Avastin) was injected into both eyes. Eighteen months after initial presentation and three months after Bevacizumab, the patient was asymptomatic, both neovascular membranes were inactive, and visual acuity had improved to 20/70 OD and 20/100 OS.

Conclusions: We report the first case of aggressive bilateral extramacular choroidal neovascular membranes in a patient with wet AMD. The pathophysiology that causes AMD to target the macula and fovea in most cases, but the extramacular region in this case, has yet to be elucidated.

Natasha A Naik*, Yannis M Paulus and Darius M Moshfeghi 


Article Image 1

Intraocular Lens Power Calculation after Intracorneal Ring Segment Surgery for the Treatment of Post-LASIK Ectasia

Objective: To describe the method of Intraocular lens (IOL) power calculation in eyes after Intracorneal Ring Segment (ICRS) surgery for the treatment of post-LASIK ectasia.

Design: Retrospective observational case-series.

Participants: Three eyes of 2 patients were included in this study.

Methods: Corneal curvature in the central effective optical zone was averaged using corneal topography and k-reading (Kr) was calculated using Jarade IR method for Kr after LASIK. The calculated Kr was used in SRK-T formula for IOL calculation. Accuracy of this IOL calculation method was judged using the manifest refraction outcome after cataract surgery. All eyes were targeted for emmetropia after cataract.

Results: In our series, one eye developed cataract after ICRS surgery for the treatment of ectasia after hyperopic LASIK (+4 D) and 2 eyes developed cataract after ICRS surgery for the treatment of ectasia after myoic LASIK (-10 D). The spherical equivalent of manifest refraction after cataract surgery was within 1.25 D in all eyes.

Conclusion: Using the average corneal curvature in the central effective optical zone to calculate Kr “by Jarade IR” method was found to be accurate in calculating IOL power in ectatic eyes treated by ICRS surgery

Elias Jarade¹#, Ali Dirani¹,²#, Ali Fadlallah MD¹,², Elias Chelala², Henry Fakhoury¹, George Cherfan¹*


Article Image 1

Unilateral Choroidal Osteoma with Choroidal Neovascularization

Purpose: Choroidal osteoma is a rare tumor which features intraocular bone formation. This tumor can be complicated by choroidal neovascularization which is a cause of impaired vision in this condition. We present a case of choroidal osteoma with choroidal neovascularization as a complication.

Methods: Case report with clinical and angiographic correlation.

Results: A 16 year old female presented with a choroidal osteoma in the left eye complicated by choroidal neovascularization. The patient was treated with Bevacizumab; an intravitreal anti-Vascular Endothelial Growth Factor (Anti-VEGF). Following treatment there was improvement in vision as well as resolution of the choroidal neovascular membrane.

Conclusion: We present a case of choroidal osteoma with choroidal neovascular membranes. Subfoveal Choroidal Neovascularization (CNV) associated with choroidal osteoma may be safely treated with bevacizumab. Larger studies are required to fully evaluate the management and long-term outcomes of anti-VEGF therapy for CNV associated with choroidal osteoma.

Courtney M Crawford¹ and Okezie C Igboeli²*


Article Image 1

Retinal Hemorrhage after Infliximab Use

Infliximab is a chimeric monoclonal antibody against Tumor Necrosis Factor-α (TNF-α), initially developed for treatment of rheumatoid arthritis and inflammatory bowel disease

Es Souiri J¹, Abourazzak FE¹, Andaloussi Idrissi B² and Harzy T¹*


Article Image 1

Giant Retinal Tear Retinal Detachment Etiologies, Surgical Outcome and Incidence of Recurrent Retinal Detachment after Silicon Oil Removal

Purpose: To evaluate etiologies, management, and outcomes of patients with Giant Retinal Tears (GRT) undergoing primary surgery at tertiary referral center.

Methods: A Retrospective, consecutive case series of 94 patients with at least 3 months follow up after silicon oil removal. 57 eyes (60.6%) underwent vitrectomy, 36 eyes (38.3%) underwent combined vitrectomy with buckling and 1 eye (1.1%) underwent scleral buckling. Perfluorocarbon (PFCL) heavy liquid to flatten GRT f lap intraoperative has been used then PFCL air exchange then air silicon exchange in all eyes undergoing vitrectomy. Fellow eye was observed for retinal detachment.

Results: Idiopathic cause constitute 47 eyes (50%), 25 eyes (26.6%) are myopic and 22 eyes (23.4%) have history of trauma. 85 eyes (90.4%) achieved anatomic success. Visual acuity at the last follow-up was at least 20/400 in 71 eyes (75.5%) of patients. Recurrent retinal detachment after Silicon Oil Removal (SOR) was found in 21 eyes (22.3%) of which, 50% had Proliferative Vitreoretinopathy Grade C (PVR-C) or more (p value 0.03) and 20% had GRT size more than 180° (p value 0.04). Pars Plana Vitrectomy (PPV) alone (p value 0.89) or combined PPV with buckling (p value 0.98) have no significant correlation with recurrent Retinal Detachment (RD). 21% of the fellow eye had retinal detachment.

Conclusion: Idiopathic cause constitutes the majority 50%. Patients with GRT who underwent surgery achieved high anatomic success rate. PVR-C or more remain the most significant risk factor for recurrent RD after SOR whereas PPV alone or combined PPV with buckling have no significant correlation with recurrent RD.

 

Eman Abo Taleb


Article Image 1

Macular Hole Surgery after Treatment with Ocriplasmin for Full Thickness Idiopathic Macular Holes with Vitreomacular Traction

Purpose: To report the efficacy of Ocriplasmin in the treatment of small-medium sized idiopathic full thickness Macular Holes with focal Vitreomacular traction in comparison with vitreous surgery.

Methods: Retrospective observational single-centre small case series (n=6) studythat included patients who underwent vitrectomy after unsuccessful treatment ofsmall-medium size full thickness Idiopathic macular holes with ocriplasmin.

Results: 6 eyes with full-thickness macular holes and VMT were included, whereby in 4 eyes an epiretinal membrane was present (66.7%). Resolution of VMT after intravitreal injection of ocriplasmin was shown in three out of six eyes (50%) and in all six eyes after vitrectomy (100%). Of all six eyes presenting macular holes with a mean size of 265 µm ± 109 µm at baseline visit, five eyes showed persistent macular holes at the second follow-up visit with a mean size of 335 µm ± 166 µm. After vitrectomy no macular hole could be detected at the f inal follow-up visit.

Conclusion: We present our clinical experience with intravitreous injection of Ocriplasmin to confirm the presumed therapeutic effect in patients suffering from Vitreomacular Traction (VMT) with small-medium sizedfull thickness Macular holes (MH). Small macular holes could frequently be closed with only Ocriplasmin and without surgery with a 17% closure rate. Enlargement in all holes that failed to close with Ocriplasmin was observed in all treated eyes which makes us believe that the VMT could have a Protective role. Ellipsoid zone disruptions were evident in 50% of treated eyes and more common in eyes with successful VMT release. Although data on Ocriplasmin from several studies remain controversial but so far the results are consistent with the results and recommendations of other clinical studies and the European Medicine Agency. We agree that replacing vitrectomy for MHs with one injection of Ocriplasmin would be a very attractive option but so far Pars plana vitrectomy remain the treatment of choice for most eyes with MHs. Further Work is recommended to reveal the Cause of the ellipsoid zone Changes, the mechanisms of tractional forces and to investigate the Long term side effects of Ocriplasmin.

Khaled Helaiwa¹,², Ammar Heider², KU Bartz-Schmidt¹ and Kai Januschowski¹,²*


Article Image 1

Comparing Refractive Outcomes of Standard Phacoemulsification with Femtosecond Laser-Assisted Cataract during the Initial Learning Curve and with More Experience

Purpose: To analyze and compare the refractive outcomes of standard phacoemulsification with femtosecond laser-assisted cataract surgery performed during the initial learning curve and a year later by experienced surgeons.

Methods: This single-center retrospective study was divided into 3 groups: Group 1, 63 patients who underwent standard phacoemulsification (control group) prior to femtosecond laser acquisition by two anterior segment surgeons; Group 2, the first 104 patients who underwent femtosecond laser-assisted cataract surgery by the same surgeons from Feb 19, 2014 to April 30, 2014 (learning curve group) and Group 3,108 patients who underwent femtosecond laser-assisted cataract surgery by the same surgeons a year later from Feb, 2015 until June 30, 2015 (experienced group).

Results: Mean absolute refraction prediction errors were 0.37 ± 0.25 Diopters (D) in the control group, 0.30 ± 0.24 D in the “learning group” and 0.30 ± 0.24 D in the experienced group with no significant differences among groups. The percentages of eyes within 0.5 D of the targeted refraction were 69.8%, 90.5% and 82.5% in the control group, learning group, and experienced group, respectively (p

Conclusion: There was no statistically significant difference in the mean postoperative refraction prediction errors between femtosecond laser-assisted cataract surgery and standard phacoemulsification in either the learning curve or experienced group. However, a higher percentage of patients were within 0.5 D of the targeted refraction in the learning curve femtosecond laser-assisted cataract surgery group compared with the standard phacoemulsification group.

Ildamaris Montes de Oca, Sumitra S Khandelwal, Eric J Kim, Tim Soeken, Ryan Barrett, Li Wang, Mitchell P Weikert, Douglas D Koch and Zaina Al-Mohtaseb*